ozempic lawsuit Updates
Ozempic/Wegovy Vision Loss Cases Seek Multicounty Litigation in New Jersey State Court
Over 30 plaintiffs alleging permanent vision loss (NAION) from Novo Nordisk’s Ozempic and Wegovy have petitioned for multicounty litigation (MCL) coordination in New Jersey state court—a 50% increase since mid-June. Cases are currently dispersed across eight Middlesex County judges, involving plaintiffs from 13 states. The proposed MCL would centralize pretrial proceedings (discovery, motions, expert challenges) while preserving individual trials, mirroring federal MDL efficiency but avoiding its procedural bottlenecks. This state-court strategy reflects a growing trend: plaintiffs leverage state venues to bypass stringent federal evidentiary gatekeeping and enhance settlement leverage through bellwether trials. The move signals intensified pressure on Novo Nordisk outside the parallel federal MDL.
Swedish Study Links Semaglutide to Higher Retinal Vein Occlusion Risk
A new observational study of over 800,000 diabetic patients in Sweden suggests semaglutide (e.g., Ozempic) is associated with a 1.6-fold increased risk of retinal vein occlusion (RVO), a serious condition causing sudden vision loss. Researchers compared users of GLP-1 receptor agonists to those on traditional diabetes therapies. While the study authors emphasize that causation is not confirmed and further research is needed, these findings contribute to mounting evidence of potential vascular eye risks tied to semaglutide. The data may complicate Novo Nordisk’s legal defense in existing lawsuits alleging semaglutide caused non-arteritic anterior ischemic optic neuropathy (NAION), as RVO represents another vision-related adverse event under scrutiny.
EU Expands Ozempic Use for Heart Condition, Raising Concerns Over Side Effects
European Union drug regulators have approved Ozempic for the treatment of peripheral artery disease (PAD), a heart condition that limits mobility in people with diabetes. Clinical trials showed that Ozempic helped some patients walk longer distances, prompting regulators to broaden its prescribing guidelines. While this expansion may benefit some patients, it also increases the number of individuals exposed to Ozempic’s known risks. As a result, legal experts anticipate a rise in lawsuits against Novo Nordisk, with more patients potentially experiencing severe side effects, such as stomach paralysis, vision loss, or other health complications linked to the drug
Plaintiffs Seek New Jersey Multicounty Litigation for Ozempic Vision Loss Claims
In late June, 21 plaintiffs filed a request to consolidate their lawsuits in New Jersey state court through multicounty litigation (MCL), aiming to pursue joint legal action against Novo Nordisk, the maker of Ozempic and Wegovy. The plaintiffs allege they developed vision loss, specifically nonarteritic anterior ischemic optic neuropathy (NAION), after using the drugs. If approved, the MCL would allow state-level coordination of similar claims involving Ozempic-related eye damage. This move could provide a new legal pathway for affected individuals, while those experiencing other harms from Ozempic may still pursue claims through ongoing federal multidistrict litigation. A court decision is pending.
About the Ozempic Lawsuit
The Ozempic lawsuit has recently gained significant attention as concerns have been raised about Ozempic long term side effects, including gastroparesis, thyroid C-cell tumors, and other serious illnesses.
The core issue of the Ozempic class action lawsuit is the potential serious health risks associated with the use of Ozempic, a medication commonly prescribed to manage type 2 diabetes by controlling blood sugar levels. These issues have led to numerous reports and studies focusing on the potential dangers of the active ingredient in Ozempic, semaglutide.
People afflicted with Ozempic's long-term side effects include individuals who have been prescribed the medication for diabetes management and subsequently experienced serious health issues. Individuals who used Ozempic for weight loss were unaware of the potential risks associated with the medication.
Victims who used Ozempic for weight loss are facing significant health challenges, permanent disabilities, and, in some cases, life-threatening conditions. Many people are unaware of the risks and continue using the medication, only to experience severe health issues. Legal avenues are now available for those affected, allowing them to submit an application and seek potential compensation for the harm caused by Ozempic.
If you or a loved one have suffered serious health issues after using Ozempic, it is crucial to understand your rights and the potential for participating in the Ozempic lawsuit to seek justice and compensation.
Who Qualifies for the Ozempic Lawsuit?
There are specific criteria you must meet to potentially qualify for the Ozempic lawsuit. These requirements include.
Medication Use:
You must have been prescribed and used Ozempic between 2018 and to present.
Health Conditions: You must have been diagnosed with one of the following Ozempic side effects:
- Persistent cyclical vomiting for +4 weeks (diagnosis must be while taking the product OR within 60 days of stopping and must have experienced vomiting 1 month or more)
- Gastric Injury (diagnosis must be while taking product OR within 60 days of stopping)
- A gastric injury is any injury related to the gastrointestinal tract
- Ileus
- Gastroparesis/ stomach paralysis
- Pulmonary Aspiration (associated with anesthesia/surgery)
- Deep Vein Thrombosis (DVT)
- Esophageal Injury
If you do not have a valid cancer diagnosis from your doctor but have experienced Ozempic side effects, you may still be included in the Ozempic lawsuit.
If you meet these requirements, you may be entitled to compensation and should seek legal advice to determine your eligibility.
Which Companies Are Involved in the Ozempic Lawsuit?
Several manufacturers and their respective products are commonly implicated in the Ozempic lawsuit, however, the primary company involved is Novo Nordisk. Novo Nordisk is facing numerous lawsuits alleging that the science behind Ozempic was wrong and that it has led to serious health conditions, including gastroparesis, ileus, and other significant health issues.
These Ozempic lawsuits claim that Novo Nordisk failed to adequately warn users about the potential risks associated with the drug's active ingredient, semaglutide. As more evidence emerges linking to Ozempic's long-term side effects, the number of cases against the company is expected to increase. If you or a loved one have experienced adverse health effects after using Ozempic, you may qualify to join the ongoing litigation.
How Much Compensation Should You Expect In Your Ozempic Lawsuit?
Determining a typical settlement amount in the Ozempic lawsuit is complex due to the unique nature of each case. Factors such as the severity of the illness, the strength of the evidence, jury decisions, and the skill of the lawyers involved all influence the settlement amount.
As of now, the Ozempic lawsuits are in the early stages, and no global settlements or jury trials have been reported. However, based on other pharmaceutical litigation and the current scope of the Ozempic cases, potential settlement amounts can be anticipated based on the type and extent of harm suffered by plaintiffs.
Add Comment